Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrei Leonov

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
[<sup>11</sup>C]MODAG-001-towards a PET tracer targeting α-synuclein aggregatesLaura Kuebler, Sabrina Buss, Andrei Leonov, et al.
Nature Communications|September 14, 2022
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrilsLeif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Ebiomedicine|May 2, 2022
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJohannes Levin, Nand Sing, Sue Melbourne, et al.
Nature Communications|October 3, 2025
Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formationMookyoung Han, Benedikt Frieg, Dirk Matthes, et al.
Acta Neuropathologica|October 7, 2015
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesJens Wagner, Sybille Krauss, Song Shi, et al.
Alzheimer'S Research & Therapy|August 3, 2019
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tauMatthias Brendel, Maximilian Deussing, Tanja Blume, et al.
EMBO Molecular Medicine|December 7, 2017
The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathologyAna Martinez Hernandez, Hendrik Urbanke, Alan L Gillman, et al.
Science Translational Medicine|May 27, 2026
The PET tracer [<sup>11</sup>C]MODAG-005 targets alpha-synuclein aggregates in the brainRan Sing Saw, Sabrina Haas, Felix Schmidt, et al.
Acta Neuropathologica|April 23, 2013
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseJens Wagner, Sergey Ryazanov, Andrei Leonov, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
[<sup>11</sup>C]MODAG-001-towards a PET tracer targeting α-synuclein aggregatesLaura Kuebler, Sabrina Buss, Andrei Leonov, et al.
Nature Communications|September 14, 2022
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrilsLeif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Ebiomedicine|May 2, 2022
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJohannes Levin, Nand Sing, Sue Melbourne, et al.
Nature Communications|October 3, 2025
Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formationMookyoung Han, Benedikt Frieg, Dirk Matthes, et al.
Acta Neuropathologica|October 7, 2015
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesJens Wagner, Sybille Krauss, Song Shi, et al.
Alzheimer'S Research & Therapy|August 3, 2019
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tauMatthias Brendel, Maximilian Deussing, Tanja Blume, et al.
EMBO Molecular Medicine|December 7, 2017
The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathologyAna Martinez Hernandez, Hendrik Urbanke, Alan L Gillman, et al.
Science Translational Medicine|May 27, 2026
The PET tracer [<sup>11</sup>C]MODAG-005 targets alpha-synuclein aggregates in the brainRan Sing Saw, Sabrina Haas, Felix Schmidt, et al.
Acta Neuropathologica|April 23, 2013
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseJens Wagner, Sergey Ryazanov, Andrei Leonov, et al.
Pageof 5